Immunovant shareholders elect three directors, ratify EY, approve exec compensation

Immunovant, Inc.

Peter Salzmann (98.5M for, 17.7M withheld), Douglas Hughes (96.6M for, 19.6M withheld), George Migausky (96.6M for, 19.7M withheld) elected to board.
Ratification of Ernst & Young as independent auditor for FY2024: 121,206,460 for, 5,261 against, 1,355 abstain.
Non-binding advisory approval of named executive officer compensation: 115,397,185 for, 825,452 against, 8,173 abstain, 4,982,266 broker non-votes.
Annual meeting turnout ~93% of outstanding shares (121,213,076 shares represented).
All three proposals passed; no material changes to governance disclosed.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunovant, Inc. shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers at the 2023-08-21 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-08-21

Exact text from the filing

Proposal 3- Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 115,397,185 825,452 8,173 4,982,266

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunovant, Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-08-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-08-21

Exact text from the filing

Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant’s independent registered public accounting firm for the year ending March 31, 2024, by the following votes: Votes For Votes Against Votes Abstain 121,206,460 5,261 1,355

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunovant, Inc. shareholders approved Election of Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky as directors at the 2023-08-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-08-21

Exact text from the filing

Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant’s Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Salzmann, M.D., M.B.A. 98,532,525 17,698,285 4,982,266 Douglas Hughes 96,590,902 19,639,908 4,982,266 George Migausky 96,550,901 19,679,909 4,982,266

View on SEC.gov

545 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-23-000097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.